Alnylam Pharmaceuticals has completed enrollment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). Interim results from this Phase II study showed that ALN-TTR02 achieved as mich as 93% knockdown of TTR. The candidate’s activity was found to be rapid, dose dependent, and durable, with similar levels of TTR knockdown observed toward both wild-type and mutant protein. In addition, ALN-TTR02 w...